GlassScriptPhysician profile
Kevin W Nash
NPI 1518988260
$6,522.68
in general payments reported to CMS, 2019-2025
32 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $173 · 2021: $747 · 2022: $3,777 · 2023: $736 · 2024: $555 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Education: $19.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.65 |
| Education | $19.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $3,686.51 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $400.16 | 2021-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $269.12 | 2020-2025 | Ultomiris, Strensiq |
| Vifor Pharma, INC. | $256.05 | 2021-2024 | Veltassa |
| Horizon Therapeutics Plc | $211.73 | 2020-2022 | |
| Glaxosmithkline, LLC. | $201.41 | 2021-2023 | Benlysta, Jesduvroq |
| Amgen INC. | $194.41 | 2022-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $156.97 | 2021-2025 | Jynarque, Voyxact |
| Ani Pharmaceuticals, INC. | $151.99 | 2022-2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $124.98 | 2019 | |
| Opko Pharmaceuticals, LLC | $114.33 | 2021-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $107.31 | 2022-2024 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $88.01 | 2022-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $86.46 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $54.11 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $48.21 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.41 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $38.53 | 2023 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.57 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $25.39 | 2024 | |
| Shire North American Group INC | $23.90 | 2019 | |
| Alvogen INC | $23.86 | 2024 | Teriparatide |
| Recor Medical INC | $21.94 | 2024 | Paradise Renal Denervation System |
| Novo Nordisk INC | $21.04 | 2025 | |
| Janssen Biotech, INC. | $20.85 | 2025 | Tremfya |
| Amag Pharmaceuticals, INC. | $20.45 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.40 | 2021 | |
| Kyowa Kirin, INC. | $19.65 | 2024 | Crysvita |
| Ardelyx, INC. | $19.55 | 2025 | Ibsrela |
| Medtronic, INC. | $17.07 | 2023 | Onyx Frontier |
| Daiichi Sankyo INC. | $16.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.